Blood:抗磷脂抗体通过内皮细胞中形成的apoER2-Dab2-SHC1复合体激活PP2A诱导血栓形成

2018-03-04 MedSci MedSci原创

中心点:激活内皮细胞的PP2A是aPL诱导小鼠血栓形成的基础。内皮ApoER2充当aPL诱导组装的包含Dab2和SHC1的可激活PP2A的蛋白复合物的支架。摘要:对于抗磷脂抗体综合征(APS),抗磷脂抗体(aPL)识别β2糖蛋白(β2GPI)会促进血栓形成,而根据临床前研究提示,这是因为内皮NO合成酶(eNOS)通过ApoER2依赖性方式发挥拮抗作用。但其潜在的分子机制尚未明确。近日Blood上发

中心点:

激活内皮细胞的PP2A是aPL诱导小鼠血栓形成的基础。

内皮ApoER2充当aPL诱导组装的包含Dab2和SHC1的可激活PP2A的蛋白复合物的支架。

摘要:

对于抗磷脂抗体综合征(APS),抗磷脂抗体(aPL)识别β2糖蛋白(β2GPI)会促进血栓形成,而根据临床前研究提示,这是因为内皮NO合成酶(eNOS)通过ApoER2依赖性方式发挥拮抗作用。但其潜在的分子机制尚未明确。近日Blood上发表了一篇相关文献。

研究人员发现在内皮细胞中,apoER2胞内末端充作aPL诱导的组装的支架,激活异源性三聚体蛋白磷酸酶PP2A。apoER2 NPXY模体招募Dab2,通过亮氨酸甲基转移酶-1促进激活PP2A催化亚基的L309甲基化。同时,SHC1将PP2A支架亚基和两个不同的介导抑制Akt和eNOS去磷酸化的PP2A调节亚基一起募集至富含脯氨酸的apoER2的C末端。

综上所述,本研究表明上述所提及的内皮细胞内的过程,是aPL诱导的血栓形成的基础。通过阐述APS相关血栓形成病理过程的复杂性,为治疗相关疾病提供新的潜在靶点。

原始出处:

Anastasia Sacharidou, et al.Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endotheliumBlood  2018  :blood-2017-11-814681;  doi: https://doi.org/10.1182/blood-2017-11-814681

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937734, encodeId=c6bb193e73445, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 26 20:13:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722149, encodeId=de4f1e2214930, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Apr 20 13:13:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590594, encodeId=264c1590594a1, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 06 04:13:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292944, encodeId=de752929442c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Mar 04 14:25:22 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292934, encodeId=e3b229293469, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Mar 04 13:32:29 CST 2018, time=2018-03-04, status=1, ipAttribution=)]
    2018-09-26 bioon1
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937734, encodeId=c6bb193e73445, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 26 20:13:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722149, encodeId=de4f1e2214930, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Apr 20 13:13:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590594, encodeId=264c1590594a1, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 06 04:13:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292944, encodeId=de752929442c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Mar 04 14:25:22 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292934, encodeId=e3b229293469, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Mar 04 13:32:29 CST 2018, time=2018-03-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937734, encodeId=c6bb193e73445, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 26 20:13:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722149, encodeId=de4f1e2214930, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Apr 20 13:13:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590594, encodeId=264c1590594a1, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 06 04:13:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292944, encodeId=de752929442c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Mar 04 14:25:22 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292934, encodeId=e3b229293469, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Mar 04 13:32:29 CST 2018, time=2018-03-04, status=1, ipAttribution=)]
    2018-03-06 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937734, encodeId=c6bb193e73445, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 26 20:13:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722149, encodeId=de4f1e2214930, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Apr 20 13:13:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590594, encodeId=264c1590594a1, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 06 04:13:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292944, encodeId=de752929442c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Mar 04 14:25:22 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292934, encodeId=e3b229293469, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Mar 04 13:32:29 CST 2018, time=2018-03-04, status=1, ipAttribution=)]
    2018-03-04 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1937734, encodeId=c6bb193e73445, content=<a href='/topic/show?id=ca28426010b' target=_blank style='color:#2F92EE;'>#复合体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42601, encryptionId=ca28426010b, topicName=复合体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Wed Sep 26 20:13:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1722149, encodeId=de4f1e2214930, content=<a href='/topic/show?id=3d955558116' target=_blank style='color:#2F92EE;'>#抗磷脂抗体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55581, encryptionId=3d955558116, topicName=抗磷脂抗体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e5833182948, createdName=whmdzju, createdTime=Fri Apr 20 13:13:00 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590594, encodeId=264c1590594a1, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Mar 06 04:13:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292944, encodeId=de752929442c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Mar 04 14:25:22 CST 2018, time=2018-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=292934, encodeId=e3b229293469, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Mar 04 13:32:29 CST 2018, time=2018-03-04, status=1, ipAttribution=)]
    2018-03-04 sunfeifeiyang

    0

相关资讯

Blood:从微流体看血小板和活化内皮的相互作用。

本综述主要是基于体外流式实验和体内血栓形成实验的交叉参考对血小板-内皮界面进行阐述。

Blood:Csk和磷酸酶CD148具有维持血小板稳态的作用

Src家族激酶(SFKs)协调血小板的信号激活和扩散,但目前尚不清楚其如何调控。本研究中,研究人员发现敲除小鼠的Src激酶(Csk)的C末端和受体样蛋白酪氨酸-磷酸酶CD148可导致血小板SFK活性增强,证明上述蛋白对调节血小板反应至关重要。与此相矛盾的,Csk/CD148-缺陷小鼠却表现为血栓形成减少、受伤后出血增加,而不是血栓形成的表现。该现象涉及一个多重负反馈调节机制,包括下调以免疫受体酪氨

Blood:发现新的且可减少出血风险的抗血栓形成机制和疗法!

目前抗血栓形成药物,包括广泛应用的抗血小板药物和抗凝血剂,均有引发出血的风险、增加发病率和死亡率。然而,有新的实验证据提示,止血和血栓形成的分子和细胞机制可相互分离,从而可开发新的能降低出血风险的抗血栓治疗靶点。Blood上近期发表一篇文章,总结了最新出现的一些抗血栓形成的病例。从血小板和凝血系统,两条导致血栓形成的主要途径各自的特异性活性出发,可使人确信,生理性止血和病理性血栓形成机制不同,可选

Blood:急性血小板减少后,新产生的幼稚血小板常出现GPVI信号缺陷。

血管损伤的部位,暴露的内皮下胶原通过与血小板表面的免疫受体酪氨酸激活模体(ITAM)-偶联糖蛋白(GP)VI相互作用,,从而激活血小板和血栓形成。血小板是由巨核细胞(MKs)的细胞质衍生而来,巨噬细胞将巨大的血小板前体延伸到骨髓(BM)窦,进而脱落入血,最终在血液中形成正常大小的血小板并成熟。在胶原蛋白富集的BM环境中,MKs活化以及形成血小板前体的过程受抑制的机制仍不明确。本研究中,研究人员发现

Ann Intern Med:骨髓增殖性肿瘤患者动脉和静脉血栓形成风险分析!

由此可见,在所有年龄组的MPNs患者中动脉和静脉血栓形成发生率与相匹配的对照者相比率显著提高,在诊断后不久发生率最高。随着时间的推移静脉血栓形成率下降可能反映了临床治疗的进展。

JAHA:非血小板血栓素生成的连续测定对心脏手术后长期结局的不同影响

冠脉旁路移植手术后的长期非血小板血栓素生成是5年不良结局包括死亡的一个新危险因素。